Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-05271 |
CD20 Protein, Human, Recombinant (TrxA), Biotinylated
MS4A2,CD20,LEU-16,CVID5,membrane-spanning ... |
Human | E. coli |
CD20 Protein, Human, Recombinant (TrxA), Biotinylated is expressed in E. coli expression system with TrxA tag. The predicted molecular weight is 23.9 kDa and the accession number is A0A024R507. | |||
TMPY-02819 |
CD20 Protein, Human, Recombinant (aa 213-297, His)
Bp35,MS4A2,LEU-16,CVID5,MS4A1,membrane-spa... |
Human | HEK293 Cells |
CD20 Protein, Human, Recombinant (aa 213-297, His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 12.1 kDa and the accession number is A0A024R507. | |||
TMPY-04615 |
CD20 Protein, Human, Recombinant (TrxA)
MS4A2,CD20,CVID5,S7,Bp35,membrane-spanning 4-domains, subfam... |
Human | E. coli |
CD20 Protein, Human, Recombinant (TrxA) is expressed in E. coli expression system with TrxA tag. The predicted molecular weight is 23.9 kDa and the accession number is A0A024R507. | |||
TMPK-00183 |
CD20 Protein, Human, Recombinant (His & Avi)
MS4A2,Ly-44,LEU-16,MS4A1,Bp35,CD20 recepto... |
Human | E. coli |
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. CD20... | |||
TMPK-00184 |
CD20 Protein, Human, Recombinant (His & Avi), Biotinylated
MS4A-1,CD20,B-lymphocyte surface antigen B1,Membrane-spannin... |
Human | E. coli |
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. CD20... | |||
TMPJ-00184 |
CD20 Protein, Human, Recombinant (Flag)
B-lymphocyte surface antigen B1,B-lymphocyte antigen CD20,Me... |
Human | HEK293 Cells |
CD20 Protein, Human, Recombinant (Flag) is expressed in HEK293 mammalian cells with C-Flag tag. The predicted molecular weight is 33-37 kDa and the accession number is P11836. | |||
TMPJ-00185 |
CD20 Protein, Human, Recombinant (His & Flag)
CD20,Membrane-spanning 4-domains subfamily A member 1,B-lymp... |
Human | HEK293 Cells |
CD20 Protein, Human, Recombinant (His & Flag) is expressed in HEK293 mammalian cells with C-6xHis-Flag tag. The predicted molecular weight is 34-40 kDa and the accession number is P11836. | |||
TMPH-02342 |
Collagenase Protein, Hypoderma lineatum, Recombinant (His & Myc)
Collagenase,HC,Hypodermin C |
Hypoderma lineatum | E. coli |
This enzyme is a serine protease capable of degrading the native triple helix of collagen. Also cleaves the B chain of insulin at the 15-Leu-|-Try-16 and 22-Arg-|-Gly-23 bonds. Hydrolyzes casein, but not Px-Pro-Leu-Gly-Pro-DArg, BzArgNHPh, AcTyrNHPh, 2-naphthyl phosphate, 2-naphthyl butyrate, 2-naphthyl caprylate, 2-naphthyl myristate, L-leucine 2-2-naphthylamide, L-valine 2-naphthylamide, L-cysteine 2-naphthylamide or L-glutarylphenylalanine 2-naphthylamide. | |||
TMPH-00534 |
Gelatinase Protein, Enterococcus faecalis, Recombinant (His & SUMO)
|
Enterococcus faecalis | E. coli |
Metalloprotease capable of the hydrolysis of insoluble hydrophobic substrates. Hydrolyzes azocoll and gelatin and, at a lower rate, soluble and insoluble collagens. Does not cleave short synthetic peptides. Preferentially hydrolyzes the 24-Phe-|-Phe-25 bond in the insulin B-chain, followed by the 5-His-|-Leu-6 bond. Inactivates endothelin-1, primarily by cleavage of the 5-Ser-|-Leu-6 and 16-His-|-Leu-17 bonds. Hydrolyzes the alpha chain of C3 to generate a C3b-like protein. Inhibits complement-m... | |||
TMPY-02563 |
VSTM1 Protein, Human, Recombinant (hFc)
VSTM1,V-set and transmembrane domain containing 1,SIRL1,UNQ3... |
Human | HEK293 Cells |
V-set and transmembrane domain containing 1 (VSTM1) is a protein containing the V-set domains. V-set domains are immunoglobulin-like domains resembling the antibody variable region. V-set domains are found in many kinds of protein families, including immunoglobulin light and heavy chains, several T-cells such as CD2, CD4, CD80, and CD86, myelin membrane adhesion molecules, junction adhesion molecules (JAM), tyrosine-protein kinase receptors, and the programmed cell death protein1. VSTM1 Protein,... | |||
TMPY-02555 |
VSTM1 Protein, Human, Recombinant (His)
SIRL-1,UNQ3033,MGC119161,V-set and transmembrane do... |
Human | HEK293 Cells |
V-set and transmembrane domain containing 1 (VSTM1) is a protein containing the V-set domains. V-set domains are immunoglobulin-like domains resembling the antibody variable region. V-set domains are found in many kinds of protein families, including immunoglobulin light and heavy chains, several T-cells such as CD2, CD4, CD80, and CD86, myelin membrane adhesion molecules, junction adhesion molecules (JAM), tyrosine-protein kinase receptors, and the programmed cell death protein1. VSTM1 Protein,... |